The U.S. administration is pushing for the onshoring of pharmaceutical production. But is there a sufficient supply of qualified people to staff expanded bioprocessing operations?

To explore that question, we sit down with Eric Langer, the president and managing partner of BioPlan Associates. For more than 20 years, his firm has been publishing the Annual Report of Biopharmaceutical Manufacturing Capacity and Production, so he has the data to back up his views.

We discussed:

• The current state of bioprocessing hiring and long-term trends

• The situation at CDMOs compared to innovator companies

• The impact of geopolitics, incl ...